IO Biotech Statistics
Share Statistics
IO Biotech has 65.88M
shares outstanding. The number of shares has increased by 0%
in one year.
| Shares Outstanding | 65.88M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 29.89% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 2,741 |
| FTD / Avg. Volume | 1.62% |
Short Selling Information
The latest short interest is 167.49K, so 0.25% of the outstanding
shares have been sold short.
| Short Interest | 167.49K |
| Short % of Shares Out | 0.25% |
| Short % of Float | 0.53% |
| Short Ratio (days to cover) | 1.84 |
Valuation Ratios
The PE ratio is -0.63 and the forward
PE ratio is -1.49.
IO Biotech's PEG ratio is
0.02.
| PE Ratio | -0.63 |
| Forward PE | -1.49 |
| PS Ratio | 0 |
| Forward PS | 0.4 |
| PB Ratio | 1.29 |
| P/FCF Ratio | -0.74 |
| PEG Ratio | 0.02 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for IO Biotech.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.33,
with a Debt / Equity ratio of 0.04.
| Current Ratio | 3.33 |
| Quick Ratio | 3.33 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | -0.02 |
| Debt / FCF | -0.02 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-1,193,637.5 |
| Employee Count | 80 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 1.44M |
| Effective Tax Rate | -1.53% |
Stock Price Statistics
The stock price has increased by 25.83% in the
last 52 weeks. The beta is 0.37, so IO Biotech's
price volatility has been higher than the market average.
| Beta | 0.37 |
| 52-Week Price Change | 25.83% |
| 50-Day Moving Average | 1.04 |
| 200-Day Moving Average | 1.02 |
| Relative Strength Index (RSI) | 70.71 |
| Average Volume (20 Days) | 168,960 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -95.18M |
| Net Income | -95.49M |
| EBITDA | -93.2M |
| EBIT | -94.05M |
| Earnings Per Share (EPS) | -1.45 |
Full Income StatementBalance Sheet
The company has 60.03M in cash and 1.92M in
debt, giving a net cash position of 58.12M.
| Cash & Cash Equivalents | 60.03M |
| Total Debt | 1.92M |
| Net Cash | 58.12M |
| Retained Earnings | -359.31M |
| Total Assets | 45.74M |
| Working Capital | 24.06M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -82.35M
and capital expenditures -44K, giving a free cash flow of -82.39M.
| Operating Cash Flow | -82.35M |
| Capital Expenditures | -44K |
| Free Cash Flow | -82.39M |
| FCF Per Share | -1.25 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
